IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1)

IGF-1 LR3 (Long R3 IGF-1) is an 83-amino-acid engineered analog of human insulin-like growth factor 1 (IGF-1) designed in the late 1980s for use as a cell-culture growth supplement and as a research reagent for IGF-1 receptor biology. The molecule combines two engineering changes to the native 70-residue IGF-1 sequence: an arginine substitution at position 3 (replacing the native glutamate) and a 13-residue N-terminal extension derived from a methionyl-protein-A fusion-construct leader. Together these changes dramatically reduce the affinity of LR3 IGF-1 for the six high-affinity IGF-binding proteins (IGFBPs) that normally sequester native IGF-1 in serum and extracellular fluid.

The reduced IGFBP affinity is the defining pharmacological feature of LR3 IGF-1. Native IGF-1 in circulation is largely (>95%) complexed to IGFBPs — chiefly IGFBP-3 in a ternary complex with the acid-labile subunit — that buffer free IGF-1 levels and modulate IGF-1 receptor access. By largely escaping IGFBP binding, LR3 IGF-1 remains available to engage the IGF-1 receptor (IGF-1R) and shows substantially more potency than native IGF-1 in cell-culture systems where IGFBPs are present in the medium or secreted by the cells under study. This pharmacological signature is the reason LR3 IGF-1 was developed: it was designed for cell-culture work, not for in-vivo use.

This page is a research-only educational reference. IGF-1 LR3 supplied as a research peptide is intended for laboratory and analytical work; no therapeutic or human-use claims are made on this page.

IGF-1 LR3 is an 83-residue analog of human IGF-1. Native human IGF-1 is a 70-residue single-chain polypeptide with three intrachain disulfide bonds, structurally homologous to proinsulin. It signals through the IGF-1 receptor (IGF-1R), a transmembrane tyrosine kinase receptor structurally related to the insulin receptor, and it mediates the principal anabolic and mitogenic actions associated with the somatotropic axis downstream of growth hormone.

LR3 IGF-1 introduces two engineering changes to the native sequence. First, the glutamate at position 3 of the native molecule is replaced by arginine — the "R3" substitution. This single change reduces the binding affinity of the molecule for IGFBPs by roughly an order of magnitude while preserving binding to IGF-1R. Second, a 13-residue N-terminal extension (sequence MFPAMPLSSLFVN) is added — the "Long" part of "Long R3 IGF-1." The extension is a remnant of a methionyl-protein-A fusion construct used in the original recombinant expression and was retained in the final product because it further reduces IGFBP binding without compromising IGF-1R activation.

The net result is a molecule that binds IGF-1R with affinity comparable to native IGF-1 (within roughly two- to three-fold in published binding studies) but binds the IGFBPs with substantially reduced affinity. In cell-culture systems where IGFBPs sequester native IGF-1, LR3 IGF-1 is reported to be three- to ten-fold more biologically potent than native IGF-1 as measured by cell proliferation, protein synthesis, and other IGF-1R-mediated endpoints.

LR3 IGF-1 is widely used as a serum-free or low-serum cell-culture growth supplement, particularly for CHO cell lines used in biopharmaceutical production and for various other mammalian cell-culture applications. It is supplied in this context by major bioscience reagent suppliers as a documented cell-culture reagent. The molecule is not an approved therapy for any indication in any major jurisdiction.

It is important to be clear about what LR3 IGF-1 is not. It is not native IGF-1 — it is a deliberately engineered variant with altered IGFBP pharmacology. It is not insulin — IGF-1 and insulin are structurally related but biologically distinct, signaling through different receptors with different downstream emphasis. And it is not a medicine — the molecule is a cell-culture reagent and research tool, not a clinical product.

Native IGF-1 was identified in the late 1950s as "sulfation factor," a serum activity that mediated the effect of growth hormone on cartilage sulfation, and was later renamed somatomedin C and then IGF-1 as the molecule was purified and characterized in the 1970s. The 70-residue mature protein was sequenced, cloned, and produced recombinantly through the 1980s. Recombinant human IGF-1 (mecasermin) was eventually approved by the US FDA in 2005 for severe primary IGF-1 deficiency under the trade name Increlex.

The LR3 variant was developed in the late 1980s during the period when recombinant IGF-1 was being produced in bacterial expression systems for research use. The challenge in bacterial production was that native IGF-1 was difficult to refold correctly from inclusion bodies. Fusion-construct approaches — in which IGF-1 was expressed as a fusion with a soluble carrier protein and then cleaved — were used to improve folding yield. Researchers including Francesco DeVroede, Francis Ballard, and colleagues working with the Australian biotechnology company GroPep characterized variants of IGF-1 that retained their N-terminal extension from the fusion construct and observed that these "Long" variants were more potent than the native molecule in IGFBP-rich cell-culture systems.

The R3 substitution emerged from a separate line of structure-activity work that mapped IGFBP-binding determinants on the IGF-1 surface. Combining the R3 substitution with the N-terminal extension produced LR3 IGF-1, which became commercially available as a cell-culture supplement and a research reagent through GroPep and later (after corporate transitions) through suppliers including Sigma-Aldrich, R&D Systems, Tocris, and others. The molecule has been a routine cell-culture reagent for several decades, principally for CHO cell-based biopharmaceutical production and for various academic cell-culture applications.

LR3 IGF-1 has never been developed as a clinical therapy. The molecule was designed specifically for cell-culture applications, and its altered IGFBP pharmacology that makes it useful in vitro raises distinct considerations for in-vivo use. The native IGF-1 (mecasermin) was the molecule developed for clinical use, with FDA approval for the narrow indication of severe primary IGF-1 deficiency.

A separate body of literature on IGF-1 in muscle biology — much of it linked to work by Geoffrey Goldspring and others on the splice-variant IGF-1Eb (commonly called MGF, mechano growth factor) — provides a broader physiological context for the IGF-1 family as it relates to skeletal-muscle satellite-cell activation. MGF is structurally distinct from LR3 IGF-1; the two compounds are sometimes mentioned together in muscle-research contexts but operate by different mechanisms.

IGF-1 receptor (IGF-1R) is a heterotetrameric transmembrane tyrosine kinase receptor structurally homologous to the insulin receptor. The α-subunits sit extracellularly and provide the ligand-binding interface; the β-subunits span the membrane and provide the intracellular tyrosine kinase domain. Ligand binding triggers β-subunit transphosphorylation, recruitment of IRS adaptor proteins, and activation of the two principal downstream signaling cascades: PI3K-AKT-mTOR (anabolic/survival/protein synthesis) and Ras-Raf-MEK-ERK (mitogenic/proliferative).

The IGFBP system regulates IGF-1 bioavailability. Six high-affinity IGFBPs (IGFBP-1 through IGFBP-6) bind IGF-1 (and IGF-2) with high affinity, sequestering most circulating and extracellular IGF-1 in protein-bound form. In serum, IGFBP-3 dominates and forms a ternary complex with the acid-labile subunit (ALS) that provides the principal IGF-1 reservoir. In tissues, locally secreted IGFBPs (IGFBP-2, -4, -5, -6) modulate local IGF-1 access to IGF-1R. The IGFBP system therefore serves both to extend the circulating half-life of IGF-1 (in complex form) and to restrain free IGF-1 access to IGF-1R.

LR3 IGF-1's pharmacological distinction derives from largely escaping this IGFBP-mediated restraint. By binding the binding proteins poorly while retaining IGF-1R affinity, LR3 IGF-1 acts as if more "free" IGF-1 is available — particularly in in-vitro systems where IGFBPs are present in serum-containing or cell-secreted medium. The practical consequence is a several-fold higher potency than native IGF-1 in many cell-culture proliferation, protein synthesis, and survival assays.

The downstream consequences of IGF-1R activation are familiar from the broader IGF-1 biology literature: anabolic effects in muscle (protein synthesis, satellite-cell activation, hypertrophy), survival effects in many cell types (PI3K-AKT-mediated suppression of apoptosis), proliferative effects in mitogen-competent cells (Ras-ERK-mediated cell-cycle entry), and metabolic effects (some overlap with insulin signaling through cross-talk at the insulin/IGF-1 hybrid receptor present in tissues expressing both). The integrated phenotype of IGF-1R activation depends on the cellular context and on the relative expression of IGF-1R versus insulin receptor and of various IGFBPs.

In cell-culture applications, LR3 IGF-1 is used at nanomolar concentrations as a serum-free or low-serum growth supplement. It supports proliferation of CHO cell lines used in biopharmaceutical production, enables low-serum culture of various primary cells and cell lines that depend on IGF-1R signaling, and is used as a tool reagent for IGF-1R pharmacology studies. The reduced IGFBP affinity makes it particularly useful in systems where the secreted IGFBP profile of the cells under study would otherwise sequester added native IGF-1.

LR3 IGF-1 is an 83-residue single-chain polypeptide with three intrachain disulfide bonds in the same arrangement as native IGF-1. The molecular weight is approximately 9.1 kDa and the calculated pI is in the basic range (due to the R3 substitution and additional basic residues). The N-terminal 13-residue extension (sequence MFPAMPLSSLFVN) is appended to the otherwise-IGF-1 sequence with the E3R substitution. The B, C, A, and D domains of native IGF-1 are otherwise preserved, including the residues forming the IGF-1R binding surface.

Research-grade LR3 IGF-1 is produced recombinantly in bacterial (E. coli) expression systems. The protein is expressed in inclusion bodies, solubilized, refolded under controlled redox conditions to form the correct disulfide pattern, and purified by chromatographic methods. The molecule is supplied lyophilized, typically with carrier excipients (mannitol, trehalose, or similar) appropriate for cell-culture or research use, and is reconstituted in dilute acetic acid or sterile buffer for laboratory work. Activity is verified by cell-proliferation assays in IGF-1R-expressing cell lines.

In published cell-culture and biochemistry research, LR3 IGF-1 has several principal applications:

Cell-culture growth supplementation. LR3 IGF-1 is the canonical IGF-1 analog used as a serum-free or low-serum supplement in CHO cell culture for biopharmaceutical production. It is documented in process-development literature as a substitute for serum-supplied IGF-1, supporting cell proliferation and biomass accumulation in fed-batch bioreactor cultures. It is also used in stem cell, primary cell, and various continuous-cell-line cultures where IGF-1R signaling supports proliferation or survival.

IGF-1R pharmacology. The molecule is used as a high-potency IGF-1R agonist in radioligand binding assays, receptor activation assays (phospho-IGF-1R, phospho-AKT, phospho-ERK), and signaling-pathway-dissection studies. The reduced IGFBP affinity removes the confounding effect of IGFBP sequestration in cell-based assays that secrete IGFBPs.

IGFBP biology. By contrast, comparing the activity of native IGF-1 versus LR3 IGF-1 in a given cell-culture system provides a functional readout of IGFBP activity in that system — if LR3 is substantially more potent than native, the system has significant IGFBP-mediated sequestration; if the two are comparable, IGFBP activity is minimal.

Muscle and tissue biology. Cultured myoblasts, myotubes, and various tissue-explant models are studied with LR3 IGF-1 as a tool to probe IGF-1R-mediated anabolic and survival signaling. The R3 modification makes the molecule particularly useful in long-duration cell-culture experiments where secreted IGFBPs would otherwise progressively suppress added native IGF-1.

Comparison with MGF, native IGF-1, IGF-2, and insulin. LR3 IGF-1 sits within a family of IGF-1R-active ligands that includes native IGF-1, IGF-2, the splice variant IGF-1Eb (MGF), and to a lesser extent insulin via insulin/IGF-1 hybrid receptors. Comparative studies across this family help dissect IGF-1R-specific from receptor-cross-reactive effects.

All applications are research-context. Nothing on this page describes a clinical protocol, dose, or therapy for human use.

LR3 IGF-1 sits within the IGF-1 / IGF-1R agonist family alongside native IGF-1, the splice variant MGF, IGF-2, and recombinant insulin analogs that engage hybrid receptors.

IGF-1 LR3 is an 83-residue engineered analog of human IGF-1 designed in the late 1980s to escape IGFBP-mediated sequestration in cell-culture systems. The molecule combines an arginine substitution at position 3 (in place of native glutamate) with a 13-residue N-terminal extension derived from a fusion-construct leader. Together these changes reduce IGFBP affinity by roughly an order of magnitude while preserving IGF-1R binding, making LR3 IGF-1 several-fold more potent than native IGF-1 in IGFBP-rich cell-culture systems.

LR3 IGF-1 is widely used as a serum-free or low-serum cell-culture growth supplement, particularly for CHO cell lines in biopharmaceutical production and for various primary and continuous mammalian cell cultures that depend on IGF-1R signaling. It is also used as a high-potency IGF-1R agonist in receptor pharmacology, signaling, and biochemistry research. The molecule has never been developed as a clinical therapy; native recombinant IGF-1 (mecasermin) is the FDA-approved IGF-1 product.

This page is research educational only. IGF-1 LR3 supplied as a research peptide is intended for laboratory and analytical work; no therapeutic or human-use claims are made.